Risk of Persistent Disability in Patients With Pediatric-Onset Multiple SclerosisDamiano Baroncini, Diana Ferraro, Giuseppe Fenu et al.|JAMA Neurology|2021Cited by 62
PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective studyClara Grazia Chisari, Francesco Corea, Giancarlo Comi et al.|Journal of Neurology|2021Cited by 15
Data monitoring roadmap. The experience of the Italian Multiple Sclerosis and Related Disorders RegisterPaola Mosconi, Marinella Clerico, Tommaso Guerra et al.|Neurological Sciences|2023Cited by 9
Long-term effectiveness of natalizumab in secondary progressive multiple sclerosis: A propensity-matched studyClara Grazia Chisari, Maurizia Gatto, Umberto Aguglia et al.|Neurotherapeutics|2024Cited by 7
Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders registerRoberto Bergamaschi, Maura Danni, Ettore Beghi et al.|Neurological Sciences|2022Cited by 4